The results highlight the potential for the virus to replicate and mutate in rodents, which often live in close proximity to humans.
In a study published online on Dec. 2 in Science, researchers in the Institute for Biomedical Sciences at Georgia State University report a new candidate that has potent antiviral activity against SARS-CoV-2 when administered orally once-daily.
The novel algorithm can help scientists explore how a virus is evolving in real time and inform decision-making by government leaders.
To better reach outpatients early after a COVID-19, infection, Gilead Sciences Inc. has partnered with researchers in Georgia State University’s Center for Translational Antiviral Research to test a modified version of remdesivir that can be taken orally.
New Georgia State University nursing graduate Kanika Coburn had reasons to be anxious about finishing her nursing education during the COVID-19 pandemic. However, thanks to the private 4 South Scholarship, money for school wasn’t a concern. The scholarship, established by an anonymous Georgia State alumna, led Coburn to her dream job as a nurse in the high-risk perinatal unit of Northside Hospital-Atlanta.
A new research center led by Richard Plemper in the Institute for Biomedical Sciences will develop critical antiviral drugs to meet the challenge of existing and newly evolving threats, such as coronaviruses.
Fifty fully vaccinated members of the Georgia State community recently won $1,000 in the university’s first vaccine raffle, a thank you to faculty, staff and students for getting vaccinated.
Georgia State University was highlighted in a press briefing Oct. 6 by the White House COVID-19 response team, which recognized the university’s contribution to groundbreaking research that led to the development of molnupiravir.
A new antiviral drug tested in the Institute for Biomedical Sciences at Georgia State against influenza virus and SARS-CoV-2 has been recommended for emergency use authorization to treat COVID-19 in the United States by pharmaceutical companies that completed a Phase 3 clinical trial and achieved promising results.
Few previous studies have examined functional abnormalities in the brain, which might reveal the physiological processes that underlie prolonged mental health symptoms in COVID-19 survivors.
